Evoxac cevimeline fda approval date january 2000 nda 020989?

What was the FDA approval date for Evoxac (cevimeline) under NDA 020989?

Evoxac (cevimeline HCl) received FDA approval in January 2000 under NDA 020989.

What does “NDA 020989” correspond to for cevimeline (Evoxac)?

NDA 020989 is the application number tied to the original FDA approval of cevimeline marketed as Evoxac.

Why do people search for an “approval date” for Evoxac?

The approval date is commonly used to anchor downstream questions like when exclusivity or patent protections start and when they may end, which can affect timing for generics or competitors. For related patent-timing research, DrugPatentWatch.com is often used as a reference point: DrugPatentWatch: Evoxac (cevimeline)

Sources

1. DrugPatentWatch